The other question is given Neuren’s drug was recently approved my main question is given Neuren has been granted ODD for the Rett syndrome does this give them 7 year marketing exclusivity or not? The FDA approval for Daybue didn’t mention exclusivity granted for their drug (they got paediatric rare drug PRV) so I am guessing we can also stand to get marketing approval if we fly past phase 3.
https://data-api.marketindex.com.au/api/v1/announcements/XASX:NEU:2A1436933/pdf/inline/fda-approves-daybue-the-first-treatment-for-rett-syndrome
The other question is given Neuren’s drug was recently approved...
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $91.56M | |||
| Open | High | Low | Value | Volume |
| 9.0¢ | 9.0¢ | 8.7¢ | $84.75K | 953.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 78510 | 8.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.0¢ | 147753 | 3 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
9.0¢ |
Change
0.000 ( 1.10 %) |
||||
| Open | High | Low | Volume | ||
| 9.0¢ | 9.0¢ | 8.7¢ | 300120 | ||
| Last updated 15.59pm 30/04/2024 ? | |||||
| NTI (ASX) Chart |